Skip to content

Study · Randomized controlled trial · 1987

5 results

Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials.

Amor B, Dougados M, Mery C, Dardenne M, Bach JF

Annals of the rheumatic diseases1 Jul 1987Cited by 3 (Europe PMC)

PMID3310925 (opens in a new tab)PMCIDPMC1002191 (opens in a new tab)DOI10.1136/ard.46.7.549 (opens in a new tab)PepBankPUB-03310925
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In rheumatoid arthritis trials, nonathymulin 5 mg was the most efficient tested dose, with clinical improvement in 56% versus 17% with placebo (p less than 0.02).

    In plain wordsIn rheumatoid arthritis trials, nonathymulin 5 mg was the most effective tested dose and improved clinical status more than placebo.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreaseGlobal clinical improvement
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    5 mg/dayAs given in this study (human).

    Measurements

    Clinical improvement
    56%
    nonathymulin 5 mg
    Clinical improvement
    17%
    placebo

    Source sentences

    Summary
    Nonathymulin 5 mg proved to be the most efficient dose, providing significant clinical improvement as evaluated by the global assessment of all patients who entered the trials (56% v 17% in the placebo group) (p less than 0.02) and by four objective parameters.
    1 context sentence
    Summary · context
    Two randomised double blind, placebo controlled trials have been carried out to assess the effectiveness of nonathymulin, a synthetic thymic peptide hormone, in the treatment of rheumatoid arthritis (RA) and to compare three different dosage schedules (1, 5, and 10 mg/day).
  2. 02HumanRandomized controlled trialSafety outcome

    In rheumatoid arthritis trials, nonathymulin's clinical effect was accompanied by minimal adverse effects.

    In plain wordsIn rheumatoid arthritis trials, nonathymulin's clinical effect occurred with minimal adverse effects.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    Direction not reportedAdverse effects
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    5 mg/dayAs given in this study (human).

    Source sentences

    Summary
    This effect was accompanied with minimal adverse effects and was not associated with clear changes in immunological parameters.
    2 context sentences
    Summary · context
    Nonathymulin 5 mg proved to be the most efficient dose, providing significant clinical improvement as evaluated by the global assessment of all patients who entered the trials (56% v 17% in the placebo group) (p less than 0.02) and by four objective parameters.
    Summary · context
    Two randomised double blind, placebo controlled trials have been carried out to assess the effectiveness of nonathymulin, a synthetic thymic peptide hormone, in the treatment of rheumatoid arthritis (RA) and to compare three different dosage schedules (1, 5, and 10 mg/day).
  3. 03HumanRandomized controlled trialMechanism

    In rheumatoid arthritis trials, nonathymulin's clinical effect was not associated with clear changes in immunological parameters.

    In plain wordsIn rheumatoid arthritis trials, nonathymulin's clinical effect showed no clear associated changes in immune measurements.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeImmunological parameters
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    5 mg/dayAs given in this study (human).

    Source sentences

    Summary
    This effect was accompanied with minimal adverse effects and was not associated with clear changes in immunological parameters.
    2 context sentences
    Summary · context
    Nonathymulin 5 mg proved to be the most efficient dose, providing significant clinical improvement as evaluated by the global assessment of all patients who entered the trials (56% v 17% in the placebo group) (p less than 0.02) and by four objective parameters.
    Summary · context
    Two randomised double blind, placebo controlled trials have been carried out to assess the effectiveness of nonathymulin, a synthetic thymic peptide hormone, in the treatment of rheumatoid arthritis (RA) and to compare three different dosage schedules (1, 5, and 10 mg/day).
  4. 04HumanRandomized controlled trialMechanism

    In rheumatoid arthritis trials, clinical response to nonathymulin correlated significantly with T-cell subset imbalance.

    In plain wordsIn rheumatoid arthritis trials, response to nonathymulin was linked to an imbalance in T-cell groups.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    Direction not reportedClinical response and T-cell subset imbalance correlation
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A significant correlation was observed, however, in clinical response to nonathymulin, and T cell subset imbalance was assessed using monoclonal anti-T cell antibodies and a functional suppressor T cell assay.
    1 context sentence
    Summary · context
    Two randomised double blind, placebo controlled trials have been carried out to assess the effectiveness of nonathymulin, a synthetic thymic peptide hormone, in the treatment of rheumatoid arthritis (RA) and to compare three different dosage schedules (1, 5, and 10 mg/day).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In rheumatoid arthritis trials, nonathymulin 5 mg provided significant clinical improvement as evaluated by four objective parameters.

    In plain wordsIn rheumatoid arthritis trials, nonathymulin 5 mg significantly improved clinical status as measured by four objective measures.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreaseClinical improvement by four objective parameters
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    5 mg/dayAs given in this study (human).

    Source sentences

    Summary
    Nonathymulin 5 mg proved to be the most efficient dose, providing significant clinical improvement as evaluated by the global assessment of all patients who entered the trials (56% v 17% in the placebo group) (p less than 0.02) and by four objective parameters.
    1 context sentence
    Summary · context
    Two randomised double blind, placebo controlled trials have been carried out to assess the effectiveness of nonathymulin, a synthetic thymic peptide hormone, in the treatment of rheumatoid arthritis (RA) and to compare three different dosage schedules (1, 5, and 10 mg/day).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.